Form 4: Opaleye Management Inc. Increases Stake in Eton Pharmaceuticals, Inc.

Opaleye Management Inc. reports purchasing 10,000 shares of Eton Pharmaceuticals at an average price of $7.9814 on October 23, 2024, increasing its indirect holdings.

Summary

• Opaleye Management Inc., a 10% owner of Eton Pharmaceuticals, Inc., filed a Form 4 on October 25, 2024, reporting a transaction that occurred on October 23, 2024.
• The transaction involved the purchase of 10,000 shares of common stock at a weighted average price of $7.9814.
• The shares were acquired indirectly through Opaleye, L.P.
• Following the reported transaction, Opaleye Management Inc. indirectly beneficially owns 2,770,000 shares of Eton Pharmaceuticals, Inc.
• Opaleye Management Inc. disclaims beneficial ownership of the shares except to the extent of its pecuniary interest.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing reporting a transaction. It doesn't inherently convey positive or negative sentiment, but the increased stake could be viewed as a mildly positive signal.

Positives

• Opaleye Management Inc.'s increased investment in Eton Pharmaceuticals could be interpreted as a positive signal about the company's prospects.

Management Comments

• Opaleye Management Inc. disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that Opaleye Management Inc. is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Industry Context

Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the transactions of company insiders and major shareholders.

Stakeholder Impact

• The increased stake by Opaleye Management Inc. could potentially increase investor confidence.

Key Dates